Results 211 to 220 of about 338,185 (301)

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Impact of Social Drivers of Health, Self-Efficacy, and Substance Use on COVID-19 Preventative Behaviors Among Persons Who Inject Drugs with Hepatitis C: The HERO Study. [PDF]

Int J Environ Res Public Health
Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH, The Hero Study Group.   +17 more
europepmc   +1 more source

How universities are helping fight Covid-19 [PDF]

, 2020

core  

A retrospective study of the clinical diagnosis and treatment of 158 cases of COVID-19. [PDF]

Front Public Health
Chen X, Zhang S, Lin Q, Zhuang X, Yao X, Lin L, Chen X, Lai G, Xie B.   +8 more
europepmc   +1 more source

Migration and Dispersion Evolution of Exhaled Aerosol in a Ward Under Different Ventilation Modes

Asia-Pacific Journal of Chemical Engineering, EarlyView.
ABSTRACT Wards with special functions and closure will have a higher risk of viral transmission as aerosols are an important mode of transmission for the SARS‐CoV‐2 virus. In this study, an experimental platform was built to establish the relevant parameters of the aerosol model and the aerosol propagation model according to the experimental results ...
Jingzhi Zhang, Tongqiang Xia, Qilin Yang, Yilin Cui, Ting Li, Feiqiang Guo, Kun Zhang, Rabatuly Mukhammedrakhym, Peng Hou   +8 more
wiley   +1 more source

Baseline medication profile and risk of CYP3A4 mediated drug-drug interactions among COVID-19 hospitalized patients in Spain. [PDF]

BMC Infect Dis
Martín-Quirós A, Soriano A, Tejerina-Picado F, Güerri-Fernández R, Cotarelo M, Molloy B, Fernández-Vigo E, Chacón F.   +7 more
europepmc   +1 more source

Surfactant‐Enhanced Electrospun Nanofiber Filters for Efficient Viral and Bacterial Inactivation

Journal of Applied Polymer Science, EarlyView.
In this work, electrospun polyacrylonitrile (PAN) nanofibrous filters functionalized with surfactants (CTAB, CPC, and SDS) were developed for air filtration applications. The PAN nanofiber mats enable efficient particulate matter capture while simultaneously providing antimicrobial and antiviral activity against bacteria (E. coli and S.
Edilton N. da Silva, Paulo A. M. Chagas, Gustavo C. da Mata, Felipe A. Lima, Fabiana B. Furtado, Wanderley P. de Oliveira, Rejane M. T. Grotto, Clovis W. O. de Souza, Mônica L. Aguiar, Vádila G. Guerra   +9 more
wiley   +1 more source

Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China. [PDF]

BMJ Open Respir Res
Zhu Y, Zhang Y, Yang H, Jiang C, Chen W, Zhang H, Zhang X, Wu H, Li J, An Z.   +9 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. [PDF]

Am J Health Syst Pharm
Malone DC, Seheult R, Brixner D, Oderda G, Burnett BP, Biskupiak J.   +5 more
europepmc   +1 more source